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Abstract: The impairment of skeletal muscle function is one of the most debilitating least understood
co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of
these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms
and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1)
levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the
precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal
models can help us bridge these gaps. This review aims to describe the evidence regarding the role
of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis
on ACRO. We also pinpoint future perspectives and research lines that should be considered for
improving our knowledge in the field.
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1. Introduction
Acromegaly (ACRO) is a rare chronic disfiguring and multisystem disease due to
non-suppressible growth hormone (GH) over-secretion, commonly caused by a pituitary
tumour [1]. The autonomous production of GH leads to an increase in the synthesis
and secretion of insulin-like growth factor-1 (IGF-1), mainly by the liver, which results in
somatic overgrowth, metabolic changes, and several comorbidities [1].
One of the significant disabling co-morbidities accompanying ACRO is myopathy and
its related musculoskeletal symptoms [2,3], which are significant determinants of the low
quality of life (QoL) of these patients and may persist despite disease remission [2,4–6].
However, we do not know the exact underlying mechanisms involved in its develop-
ment. Although the duration of the disease and serum GH/IGF-1 levels were shown to be
independent predictors of overall mortality and co-morbidities of ACRO [7–11], their spe-
cific role in the pathogenesis of myopathy remains to be elucidated. Besides, both GH
and IGF-1 levels are not always directly and unequivocally associated with patient QoL
and the presence and severity of co-morbidities [4,12]. For this reason, numerous efforts
are currently being made to detect active disease, pointing to other variables apart from
GH/IGF-1 [13,14].
Experimental research using cell lines and animal models is necessary to understand
better the mechanisms involved in the myopathy induced by ACRO. In this regard, there is
some evidence regarding the effects of the GH/IGF-1 axis in the muscular system and the
mechanisms by which different conditions could impact on muscle performance.
This review aims to describe the evidence regarding the role of GH and IGF-1 in
muscle anabolism, from the basic to the clinical setting, taking ACRO as the leading
paradigm in the clinical setting. The new perspectives and scientific gaps in this field to be
covered are also underlined.
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2. GH/IGF-1 Axis in Humans
Pituitary synthesis and secretion of GH is stimulated by the episodic hypothalamic
secretion of GH releasing factor and mainly inhabited by somatostatin [15]. GH stimulates
the synthesis of IGF-1 mostly by the liver, and both circulating GH and IGF-1 inhibit GH
secretion by a negative loop at both hypothalamic and pituitary levels. In addition, age,
gender, pubertal status, food, exercise, fasting, insulin, sleep and body composition play
important regulatory roles in the GH/IGF-1 axis [15].
2.1. GH Circulation, GH Receptor and Intracellular Signalling
In the circulation, GH binds to growth hormone binding protein (GHBP) which
is a soluble truncated form of the extracellular domain of the GH receptor (GHR) [16].
Therefore, bound and free GH both exist in the circulation, and GH bioavailability depends
on the pulsatile pattern of its secretion.
GHR belongs to the so-called “cytokine receptor family”, specifically part of the class
I cytokine receptor family. Cytokine receptors lack intrinsic protein tyrosine kinase (PTK)
activity and therefore rely on binding non-receptor PTKs for their signal transduction,
the so-called Janus Kinase (JAK) (Figure 1). The dimerisation induced by the binding of
GHR is the critical step in activating the signalling pathway JAK/STAT (Janus kinase/signal
transducer and activator of transcription), and binding to GHR brings two JAK2 molecules
close enough to initiate their trans-phosphorylation by recruiting STAT [17,18]. Phosphory-
lated STATSs, translocate to the nucleus, binding to specific DNA sequences and induce
the transcription of specific GH-dependent genes, thus promoting not only the synthe-
sis of IGF-1, IGF-1 binding protein (IGFBP) acid-labile sub-units (ALS), but also directly
stimulating proliferative and metabolic actions (Figure 1).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW  2  of  18 
 
 
























induce  the  transcription of specific GH‐dependent genes,  thus promoting not only  the 












Figure 1. Growth hormone (GH) receptor. The GH receptor’s dimerisation is the critical step in activating the signalling
pathway JAK/STAT. Phosphorylated STATS translocate to the nucleus, inducing the transcription of specific GH-dependent
genes, promoting mainly the synthesis of IGF-1, IGFBP acid-labile sub-units, but also, stimulating other pathways (i.e.,
IRIS and SHC) that regulate cellular proliferation, growth and metabolic events. In addition, newly synt esised IGF-1
promotes metabolic and ce lula events. IGF-1: insulin-lik growth factor, GH: growth hormone IGFBP3: IGF-1 binding
protein type 3, JAK/STAT: J nus kinase/signal transducer and transcription activator IRS: insulin receptor substrate; PI3K:
phosphatidylinositol 3-kinase; SHC: (adaptor proteins).
GHR is widely distributed throughout the body. Although GHR expression is particu-
larly important in the liver, GH receptors are found in other tissues like muscle, fat, heart,
kidney, brain and pancreas [19]. The actions of GH depend not only on the receptor but
also on the organ it stimulates; specifically, GH actions in the muscle are controversial and
depend, among other factors, on GH quantity, the time of exposition and the condition of
the subjects.
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2.2. IGF-1 Circulation, IGF-1 Receptor and Intracellular Signalling
The majority of IGF-1 circulates in the serum as a complex with the insulin-like growth
factor-binding protein IGFBP and ALS. The function of ALS is to prolong the half-life of
the IGF-I-IGFBP- binary complexes, thus regulating IGF-1 bioactivity [20].
IGF-I receptors (IGF-1R) are highly homologous to the insulin receptor. For this reason,
at high concentrations insulin cross-reacts with the IGF-1R and vice versa [21]. In cells
expressing both insulin and IGF-I receptors as in the myocyte, the receptors undergo
hetero-dimerisation (hybrid receptors), as well as homo-dimerisation. In skeletal muscle
IGF-I receptors are mainly present as hybrids, together with an excess of classical insulin
receptors regarding other mammalian tissue. Hybrid receptors bind both insulin and IGF-I,
although they have a lower insulin affinity than classical insulin receptors [21,22].
In contrast to GHR, the IGF-1R is a member of the receptor tyrosine kinase (RTK)
family. This type of receptor’s common characteristic is to have an extracellular domain
for ligand binding, a single transmembrane domain and an intracellular domain with
tyrosine kinase activity, which is activated after the ligand binds to the extracellular domain,
thus triggering the phosphorylation of Insulin Receptor Substrates (IRS). Once the IRS is
phosphorylated, it activates different pathways such as phosphatidylinositol 3-kinase or
RAS (Figure 2).







































Figure 2. IGF-1 receptor, insulin receptor and hybrid receptor. The insulin receptor (IS-R), the insulin-like growth factor
receptor type I (IGF-1-R) and the hybrid receptor belong to the family of receptor tyrosine kinases. The figure shows a
certain degree of functional overlap. After binding ligands, the receptors stimulate the phosphorylation of tyrosine residues,
which then induces phosphorylation of the Insulin Receptor Substrate (IRS) and SHC, which dock proteins for activating
the phosphatidylinositol 3-kinase (PI3K-Akt) pathway or the Ras/MAPK pathway, respectively. The PI3K-Akt pathway
is predominantly involved in metabolic actions (glucose uptake, insulin sensitivity) and cell proliferation, whereas the
RAS/MAPK pathway, is primarily involved in mitogenic effects (proliferation, growth). The number of receptors alone is
not the only determining factor in IGF-1 functi n. In this regard, the assembly and intracellular machin y disposition are
also involved.
The number of IGF-1Rs in each cell is tightly regulated by several systemic and tissue
factors, including circulating GH, thyroxine, platelet-derived growth factor, and fibroblast
growth factor. Therefore, in vivo, the number of receptors alone is not the only determining
factor in IGF-1 function [20] (Figure 2).
Despite the ubiquity of IGF-1R, the in vitro biological effects of IGF-1 are relatively
weak and often are not demonstrable except in the presence of other hormones or growth
factors, thus suggesting that IGF-1 acts as a permissive factor augment the signals of
other factors [22]. Furthermore, IGF-1 and insulin share common signalling pathways
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and functional overlap. However, IGF-1 exerts a more decisive action than insulin in
activating the RAS/MAP kinase pathway, which is related to cell growth, protein synthesis,
and apoptosis. By contrast, insulin (and in lower grade IGF-1) regulates the metabolism of
carbohydrates, lipids and proteins via PI-3K/Akt, [20,22] (Figure 2).
3. The Skeletal Muscle: A Central Link between Structural and Metabolic Function
The skeletal muscle is one of the three significant muscle tissues in the human body,
along with cardiac and smooth muscles [23]. It is crossed with a regular red and white
line pattern, giving the muscle a distinctive striated appearance, leading to it being called
striated muscle. There are three types of muscle fibres, which differ in the composition
of contractile proteins, oxidative capacity, and substrate preference for ATP production.
Type I fibres or slow-twitch fibres have low fatigability (better for endurance), and display
slow oxidative ATP, primarily from oxidative phosphorylation (a preference for fatty acids
as substrate) [24,25]. Type II or fast-twitch fibres have the highest fatigability, the highest
contraction strength, while glucose is the preferred substrate [24]. They are further divided
into Type IIa and IIb fibres. Type IIa is used for intermediate endurance contraction
and, in general, relies on aerobic/oxidative metabolism. Both types I and IIa fibres are
considered red fibres because of their high amounts of myoglobin. They also contain high
numbers of mitochondria, Type IIb fibres, (also called IIX/d) or fast glycolytic fibres, are the
fastest twitching fibres and are more insulin resistant [26]. They are also white fibres with
low levels of myoglobin and a high concentration of glycolytic enzymes and glycogen
stores. This is because they produce ATP primarily from anaerobic/glycolysis [27,28].
Thus, the fibre type composition of skeletal muscle impacts systemic energy consumption
and vice versa. Endurance or aerobic exercise increases mechanical and metabolic demand
on skeletal muscle, resulting in a switch from a fast-twitch to a slow-twitch fibre type [24].
In summary, skeletal muscle’s structural function is the most obvious one. It gives
structural support, helps maintain the body’s posture, and exerts the muscle contraction
leading to movements. Furthermore, skeletal muscle is also an important site of the
intermediary metabolism: it is a storage site for amino acids, plays a central role in
maintaining thermogenesis, acts as an energy source during starvation and, along with
the liver and adipose tissue, is crucial in the development of insulin resistance in type 2
diabetes mellitus [29].
4. GH/IGF-1 Actions in the Muscular System
The muscle is a primary target of GH and IGF-1 [30,31]. The final contribution
of GH and IGF-1 in any effect on the muscular system is not easy to establish in-vivo.
Through its receptors, GH action can be both direct and indirect through the induced
production of IGF-I. Furthermore, IGF-I is also produced locally in tissues and can act in a
paracrine/autocrine manner [32,33].
As we commented above, the muscle is much more than an organ of support and
contraction; it is a main metabolic organ. The fibre type composition of skeletal muscle
impacts systemic energy consumption and vice versa [24]. Both hormones act in the
muscle, modifying its metabolic function and structure. For example, Bramnert et al.
(2003) [34] studied both the short-term (1 week) and long-term (6 months) effects of a
low-dose (9.6 µg/kg body weight/d) GH replacement therapy or placebo on whole-body
glucose and lipid metabolism and muscle composition in 19 GH-deficient adult subjects.
GH therapy resulted in glucose metabolism deterioration and an enhanced lipid oxidation
rate in both short and long-term treatment groups, reflecting a fuel use switch from glucose
to lipids.
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the
biopsied muscles during GH therapy. These studies significantly increased our knowledge
regarding the relationship between skeletal muscle and metabolism’s fibre type composi-
tion. However, whether this muscular fibre shift represents the cause or the consequence
of insulin resistance requires further investigation.
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Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related
sarcopenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and
ageing consequences and vice versa.
4.1. GH
The first reports on the anabolic growth hormone effects dated back to 1948 and
suggested that GH inhibits proteolysis during fasting [35]. Subsequent studies have
expanded this concept [36,37].
GH is the primary hormone in the fast state; from an evolutionary point of view, when
food is scarce, GH changes fuel consumption from carbohydrates and protein to the use of
lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen balance
must be kept stable to maintain the pool of essential amino acids (EAA) involved in protein
formation. Considering this balance, different EAA radiolabelling techniques have been
used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 summarises
the results of studies assessing protein anabolism using radioisotopes. The action of GH
on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, the effects
could be different depending on the circumstances, dose and time of exposition. The acute
infusion of GH on amino acid metabolism results in a profound reduction in amino acid
oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion increased
whole-body protein synthesis without any significant changes in the synthetic rate of mus-
cle proteins. By contrast, other studies using higher doses of GH found lower proteolysis
rates. In general, acute GH infusion exerted an anabolic effect on whole-body amino-acid
(AA) metabolism, evidenced in reduced leucine oxidation, increased nonoxidative leucine
disposal, an increased amino acid disappearance rate (Rd) (all indexes of protein synthesis)
and less effect on protein breakdown (a lower rate of amino acid appearance (Ra)) probably
related with dosage. Regarding chronic GH exposure, it seems more consistent than acute
administration in promoting an increase in whole-body protein synthesis [42–44]. Similar
results have been reported after GH administration in patients with growth hormone
deficiency (GHD) [45,46], and after GH administration in malnourished patients under
haemodialysis [47].
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes.
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Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 




Brachial artery infusion 
no placebo 
0.014 μg/kg/min 
To rise locally not  
systemic 
Rd PHe  
BCA s 
release  
Locally infused GH ti-
mulates skeletal muscle 




Brachial artery infusion 
3 h GH and then 3 h 
GH + insulin/no pla-
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GH 0.014 μg/kg min  
Insulin 0.02 mU/kg/min  
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mic  
3
6 h Rd  
Ra  
BCAAs  
GH blunted the action of 
insulin 
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(9.6 μg/kg body weight/d) GH repla e ent therapy or plac bo o  whole-body glucose 
and lipid me abolism and muscle composi ion in 19 GH-deficient adult subjects. GH ther-
apy resulted in gluc se metabolism deterioration and a  enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Further ore, there was a shift toward more insulin-resista t type II X f bres in the 
biopsied muscl s during GH herapy. These studi s significantly increased our 
knowledge regardi g the relationship between ke etal mu cle and m tabolism’s fibre 
type composition. Howeve , wheth r this muscular fibre sh ft represents the cause or the 
consequence f insulin resistanc  requires furth r investigat on
Moreov r, GH/IGF1 lev ls have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefor , GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
Th  first r ports on the ana olic growth hormone ef ec s dated back to 1948 and sug-
ges ed that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the p imary hormo e in the fast state;  an evolution ry point of view,
when food i  scarce, GH changes fuel consumption f m carbohydrates and protein to he 
use of lipids, allowing for the co serva io of vital protein s ores [38]. Humans’ nitrogen 
bala ce must be kep  stable to aintain t e pool of essential amino cids (EAA) involved 
in prot in formation. Considering this balance, different EAA radiolabelling techniques 
have been u d to eval ate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of s udies assessing protein abolism usi g ra ioisotopes. The 
action o  GH on muscle tissue is ai ly anabolic and ha  littl  effect on proteolysis. Still, 
the eff cts could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid etabolism results in a profound reductio  in 
ami o acid oxidation [36,37,39–41]. Some studies demonstrated that cut  GH infusion 
increased whole-body protein sy hesis without any sig ificant chang s in the synthetic 
rate of m scle proteins. By contr st, other studies using higher doses of GH f un  l wer 
proteolysis rates. In ge eral, acute GH i fusio exerted an anabolic effect on whol -body 
amino-acid (AA) metabolism, evidenc in reduce  leucine oxidation, increased nonox-
idative leucine dispos l, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis and less effec  on protein br akdown (a lower rate of ami o acid ap-
pearanc  (Ra)) probably rela d with dosage. Regarding chro ic GH exposure, it seems 
mor  consistent than acute ad inistration i  promoting an incr ase in whole-body pro-
tein synthesis [42–44]. Similar r sults have been reported after GH administrat on in pa-
tients with growth hormone defici ncy (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most r levant studies wit  GH evalu ting protein ana olism using radioisotopes. 




Brachial rtery infusion 
no placebo 
0.014 μg/kg/min 
To rise locally not  
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Rd PHe  
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3 h  and the  3 h 
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To ri e locally not syste-
mic  
3 h Rd  
6 h d  
Ra  
BCAAs  
GH blunted the action of 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to aintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH o  muscle tissue is mainly anabolic and has little effect on proteol sis. Still, 
the effects could be different d pe ding on th  circumstances, dose nd time f exposition. 
The acute infusion of GH on amino acid m tabolism results in a profound eductio  in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes i  th  syntheti  
rate of muscle proteins. By co tr st, oth r studies using higher doses of GH found lower 
prot olysis r tes. In general, acute GH infusion exe ted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leuci e oxidati n, increased nonox-
idativ  leuc ne disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regardi chr nic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth h rmone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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0.014 μg/kg/min 
To rise locally not  
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BCAAs  
release  
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3 h GH and then 3 h 
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cebo 
GH 0.014 μg/kg/min  
Insulin 0.02 mU/kg/min  
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GH blunted the action of 
insulin 
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(9.6 μ /kg ody weight/d) GH re lacement therapy or placebo on whole- ody glucose 
and lipi  metabolism and muscle compositio  i  19 GH-deficient ult subject . GH ther-
apy resulted i  lucos  metab lism deterioration and an e hance  lipid oxidati n rat in 
both short and long-t rm treatm n  group , reflecting a f el us  switch from glucos  to 
lipids. 
Furth more, there wa  a shift toward more nsuli -resistant t pe I X fibres in the 
biopsi d musc es during GH the apy. These studies sig ificantly increased our 
kn wledge regarding the relatio ship betwe  skeletal mu cle and metabolism’s fibre 
type mposition. However, whether this m scular fibr  hift represents the cause or the 
consequence of i sulin resi t nc  requi s further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skele al muscle is impaired in old r h ma s n  linked with aged related sar-
copeni  [30]. T erefore, GH/IGF-1 actio  i  the muscl  have ructural, m tabolic and 
agei g consequences and vice versa. 
4.1. GH 
The fi st reports n the anab lic rowth hor on  effects date  b ck to 1948 and sug-
gest d tha GH inhibits proteolysis during f ting [35]. Sub equent studie  ha  expan d 
this co c pt [36,37]. 
GH i  the primary hormo  in the fast state; from an ev lutio ry poi t f view, 
w n food is sc rce, GH change  fu l consumption from ca bohydr tes and protei  to the 
use  lipids, al owing for the con erv tion of vital protein tor s [38]. Huma ’ nitrogen 
balance m st  kept stable to mai tai  p ol of essential mi o acids (EAA) inv lved 
in prote  formation. Considering this bala ce, differe t EAA radiolabelling tech iques 
have been used to evaluate the effects of GH a d IGF-1 on r tein metabolism. able 1 
summarises the results of studies as essing protei  a abolism usi g radioisotopes. The 
action of GH on muscle tissue i  mainly anabolic a d s littl  effect on pr teolys s. Still, 
th  effects c uld be different depe ding on the circumstances, dose and tim  of exposition. 
The ut  infusi n of GH on am o ac d m tabolism results in a profoun  red cti n in 
am no a d ox dation [36,37,39–41]. Some stu i s dem nstrated that acut GH infusion 
increased wh l -body protein sy sis witho t any significant changes in th  synthetic 
rate of mu cle proteins. By co tras , other studies usi  igher d ses f GH found lower 
proteoly is rates. In gen ral, acute GH infusion ex rted an anabolic effect on whole-body 
ami o-acid (AA) met bolism, evidenced in re uced leu ine ox d tio , ncreased n nox-
idative leucine dispos l, an incre sed amino acid isappearance rate (Rd) (all indexes of 
pr t in synt esis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably r late  with dosage. Regardi g chronic GH exposure, it seems 
more consistent t an acute dministratio  in pr moting an increa e in whole-body pro-
ein synthesis [42–44]. Similar sults have been report d ft r  i i i  i  pa-
tients with grow h hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patie ts under haem dialysis [47]. 
Table 1. Most r levant studies with  evaluating protein anabolism using radioisotopes. 




Brachial artery infusion 
no placebo 
0.014 μg/kg/min 
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Brachial artery infusion 
3 h GH and then 3 h 
GH + insulin/no pla-
cebo 
GH 0.014 μg/kg/min  
Insulin 0.02 mU/kg/min  
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mic  
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6 h Rd  
Ra  
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GH blunted the action of 
insulin 
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(9.6 μg/kg body weight/d) GH replac ment therapy or placebo on whole-body glucose 
and lipid metabolis  a d muscle com osition in 19 GH-deficient adult subjects. GH ther-
apy resulted in gluc s  metabolism deterioration and an enhanced lipid oxidation rate in 
both sh rt and long-term tre tment groups, reflecting a fuel use switch from glucose to 
li ids. 
F rthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during H therapy. Th se studies significantly increased our 
knowledge r garding th  relationship between skeletal muscl  and metabolism’s fibre 
ty  composition. Howe er, whether this muscular fibr  shift represents the c use or the 
conseque ce of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. The efore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1.  
The first reports on t e anabolic gr wth ormone effects dated back to 1948 a d sug-
g sted that GH inhibits ro olysis during fasting [35]. Subsequ nt studies h v  expanded 
t is concept [36,37]. 
GH is the primary hormo  in the f st state; from an evol tionary point of view, 
wh n food is scarce, GH cha ge  fuel c nsumption from arbohydr tes and pr tei  to the 
s   lipids, allowing f r he conservation f vital protein stores [38]. Humans’ nitrog n 
bala ce must be kept stable to maintain the p ol of essenti l mino acids (EAA) involved 
in pr tein formati n. C n i ri g this balance, differe  EAA radi labelling techniques 
h ve be n us d t  v lu te the eff cts of GH d IGF-1 on protein metabolism. Table 1 
summ ri es the results of studies assessing p otein anabolism usi  r dioisotopes. The 
actio  of GH on muscle tissu  is mainly anabolic an  has little effect on roteolysi . Still, 
th  ffect  could be different epe ding  the circ mstances, dose and time of exposition. 
The acute infusio  of GH on amino acid m tabolism resul s in a profound re ucti n in 
a ino acid oxidation [36,37,39–41]. Some stu ies emonstrate  that acute GH i fusion 
increased whole-bo y protein synthesis without any significant changes in the synthetic 
rate of muscl  proteins. By contrast, other studies usin  higher doses of GH found lower 
p ote lysis rates. I  general, acute GH i fusion xerted a  a ab lic ffect n whole-b dy 
amino-acid (AA) met bolism, evidenced in reduced leuci e oxidatio , increased onox-
idative leucine disp sal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less ffect on protein breakdown (a low r rate of amino cid ap-
p ara ce (Ra)) prob bly related with dosage. Regarding chronic GH exposure, it seems 
more c nsist nt than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration i pa-
tients with growth hormone deficiency (GHD) [45,46], and after  administration in 
maln urished patient  u der haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism u i g radioisotopes. 
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(9.6 μg/kg body weight/d) GH r placement ther py or placebo on whole-body glucose 
and lipid metabolis  nd muscle compositio  in 19 GH-deficient adult subjects. GH th r-
apy result d in glucos  metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles du ing GH therapy. T ese studies significantly increase  our 
knowledge regard g the r lat onship betwee  sk letal muscle nd metabolism’s fibre
yp  composition. However, whether thi  muscular fi r  shift represents th  cause or the 
consequence of insulin resistance r quires further investigation. 
M reover, GH/I F1 levels hav been rela ed to ageing. In pa ticul r, IGF-1 produc-
tion by t e ke tal muscle is imp ired in lder uma s a d linked with aged related s r-
cop n a [30]. There e, GH/IGF-1 actions in the mu cle hav  struct ral, metab lic 
geing cons quences and v c  versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hor one in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenc d in reduced leu ine oxidation, increased nonox-
idative leucine disposal, an increased amino aci  disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower ra e of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consi t than acute administratio in pro oting an increase in whole-body pro-
tein synth s [42–44]. Similar result have been reported af er GH dmi i tration in pa-
tients w th growt  horm n  deficie cy (GHD) [45,46], and after GH dmini tration in 
malnourished p tients under haemodialysis [47]. 
Table 1. Most relevant s udies with GH evaluating protein a abolism using radioisotopes. 
Author Subjects Design  GH Dose  Effects  Conclusi ns 
Fryberg 
[39]  
7 e lt  
Brachial artery infusion 
no placebo 
0.014 μg/kg/min 
To rise locally not  
systemic 
d PHe  
s  
release  
Locally infused GH sti-





Brachial art ry infusion 
3 h GH and then 3 h 
GH + insulin/no pla-
cebo 
GH 0.014 μg/ g/min  
Insulin 0.02 mU/kg/min  
To rise locally not syste-
mic  
3 h Rd  
6 h Rd  
Ra  
BCAAs  
GH blunted the action of 
insulin 







GH 40 μg/d 
for 12 weeks 
protein synthesis  
Leu. Ox 
Similar muscle size, 
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(9.6 μg/kg body weight/d)  replacement herapy or placebo on whole-body glucose 
and lipid metabolism and muscl  composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidati n rate in 
both sh rt and l ng-term tr atm nt gr ups, reflecting  fuel us  switch from glucos  to 
lipids. 
F r h rmore, there was a hif  toward m re insuli -resista t typ  II X fibr s  the 
b o sied muscles during GH therapy. Th s  studies significa tl  creased our 
knowl ge r ga ding t  elati nship between skeletal uscl  a d et olism’s fibre 
type c mp siti n. However, wh the  this uscular fibre shift represents the cause r t  
consequence of ns lin resi ta ce requires further i v stiga ion. 
Mor over, GH/IGF1 lev ls have bee  related to age ng. In particular, IGF-1 roduc-
tion y th  skeletal muscle is impaired in older humans and link d with g d related sar-
copenia [30]. Th r f r , GH/IGF-  actio  in th  muscle have structur l, me abolic and 
agei g consequ nces and vice versa. 
4.1. GH 
The f rst reports on the anabolic growth hormone ffects dat d back t  1948 and sug-
gested that GH inhi its prot olysis dur g fasting [35]. Subsequent studies have expanded 
his co ept [36,37]. 
GH is the im ry hormone in he f st state; from an v luti nary p int of vi w, 
when fo  is c rce, GH changes f el consumption from c rbohydrates and protei  to the 
use f l pid , allowing for the conservatio of vital ro in sto es [38]. Humans’ nit ge  
balance must be kept stable to ma t in the po l f essen ial ami o acid  (EAA) volved 
in o e  formati n. Co sidering t is balance, differe t EAA radiolabelling tech iques 
have bee  used to eval ate the ffects f GH and IGF-1 on protein metabolism. Table 1 
su marises the results of studies assessi g pr tein anabolism using radioisot pes. The 
actio  of GH n muscle tissue is main y anabolic and h s lit le effect on proteo y is. Still, 
the effects could be different depend ng on the circumstances, dose and time of exposition.
The acute infusion of GH on amino aci metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies d monstrated tha  acute GH infusion 
incre sed whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By co trast, other studies using higher doses of GH found lower 
proteolysi  rates. In general, acute GH infu ion exerted an anabolic effect on wh le-body 
amino-acid (AA) metabolis , evide ced in reduced leucine oxidation, incr a ed nonox-
idative leucine dis osal, an in rea d amino acid isappearance rat  (Rd) (al  ind xes of 
protein synthesis) and le s effect on protei break ow  (a lower rate of m no acid ap-
pearance (R )) probably re ated with dosa e. Regarding chronic GH exp sure, it eems 
more cons ste t th n cute administra ion in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar resu ts have been reported after GH admini tra ion in pa-
tie ts with growth hormon  deficiency (GHD) [45,46], and after GH administrat on in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant st dies with GH evaluating protein anabolism using radioisotopes. 




Brachi l artery infusion 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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release  
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, th re was a shift toward mor  insulin-resistant type II X fibres in the 
biops ed muscle  during GH therapy. These stu ies significantly increased our 
k owledg  reg rding the relationship betw en skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Mor over, GH/IGF1 levels have been related o ageing. n particular, IGF-1 produc-
tion by the skeletal muscle is impaired in old r humans a d linked with aged related sar-
copenia [30]. Theref re, GH/IGF-1 actions in the muscle have structural, metabolic and 
agei g c ns quences and vice versa. 
4.1.  
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gest d that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
us  of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
bala ce must be kept table to ma tain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
ave been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
ummarises t e results of studies assessing protein anabolism using radioisotopes. The 
acti n of GH on muscl  tissue is main y anabolic and has little effect on proteolysis. Still, 
the effec s could be differe t d pending on the circumstance , dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results i  a profound reduction in 
a in  acid oxidation [36,37,39–41]. Some studies demonstr ted that acute GH infusion 
increased whole-body protein synthesis with ut any significant changes in the synthetic 
rate of muscle proteins. By co trast, other studies using higher doses of GH found lower 
proteolysis ates. In general, acute GH infusion exert d an anab lic effec   whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, i creased nonox-
idative leucine disposal, an increased amin  acid disappe rance rate (Rd) (all indexes of 
protein s nthesis) and l s effect on prote n breakdown (a lower rate of amino acid ap-
pearance (Ra)) prob bly related w th dosage. Regarding chronic GH exposure, it seems 
ore consistent than acute administration in prom t ng an increase in whole-body pro-
tein synthesis [42–44]. Similar results hav  been repor ed after GH admi istration in pa-
ti nts with growth hormone deficiency (GHD) [45,46], and after GH ad inistration in 
malnourished pati nts under haemodialysis [47]. 
Table 1. Most relevant studies with GH ev luating protein anabolism using radioisotopes. 
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(9.6 μg/kg bo y weight/d) GH r placement therapy or placebo on whole-body glucose
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deteriorati n a d an enhanced lipid oxidation rate in
oth short and ong-te m treatment groups, refl cting a fuel use switch from glucose to
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge r garding the relationship between skeletal muscle nd metabolism’s fibre 
ype composition. However, whether this muscular fibre shift represents the cause or the 
nsequence of insulin resistance requ res further investigation. 
Moreover, GH/IGF1 lev ls have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences a d vice versa. 
4.1. GH 
The first re orts on t e anabol c growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteoly is during fasting [35]. Subsequent studies have expanded
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view,
when food is scarce, GH changes fuel consumption rom carbohydrates and protein to the
use of lipids, allowing for the cons rvation of vital protein sto es [38]. Humans’ nitrogen
balance must b k pt stable o maintain the pool of essential a ino acids (EAA) involved
in protein formation. Consid ring this b lance, different EAA radiolabelling techniques
hav  been use  to evaluate the ffects f GH and IGF-1 on pr t in metabolism. Table 1
summarises the results of studies assessing prote n anabo i m using radioisotopes. The
ction of GH on muscle tissue is mainly anabol c and has little effect on proteolysis. Still, 
the effects could be ifferent depe ding on the circumstances, dose and time of xposition.
Th acute infusion of GH on amino acid metabolism results in a profound reducti n in
amin  acid oxidation [36,37,39–41]. Some tudi s demo strated that a ute GH infusion
increased whole-body protein synthesis without any significant changes in the sy thetic 
rate of m scle proteins. By contrast, other studies using higher doses of GH fou  lower
olysis rates. In gen ral, acu e GH infusion xerted an anabolic effect on whole-body 
a ino-acid (AA) metabolism, evidenced in reduced leucine xidation, increased nonox-
idative leucine dispos l, an increased amino acid disappeara e rate (Rd) (all indexes f 
protein syn hesi ) and less effec  on prot in breakd wn (  lower r t  of amino ac d ap
p arance (Ra)) probably related w th dosage. Regarding chronic GH exposure, it seems
ore con istent tha  acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished p tients under h em dialysis [47]. 
T ble 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg dy weight/d) GH re lace ent therapy or placebo on whole-body glucose 
and lipi metabolism and muscle composition i  19 GH-deficient a ult subject . GH ther-
apy resulted i  l cose me abolism deterioration and an enhan ed ipid oxidati n rate in 
both sho t an  long-t rm treatment groups, reflec ing a fuel use switch fro  glucose to 
lipids. 
Furthermore, th re was a shift towa d more insulin-res stant t pe II X fibres in the 
biopsied muscles during GH therapy. These studies sig ficantly increased our 
kn wl dg  regarding the rel tions ip b tween skeletal muscle a d m tabolism’s fibre 
type composition. However, whether th s muscular fibre shif  represents the cause or the 
consequ nce of insulin resi tanc requir s further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in old r h mans nd linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first r ports on the anabol c rowth hormone effects a e  back to 1948 and sug-
gested that GH hibits proteolysis during fasting [35]. Subsequent studies have expa ded 
this concept [36,37]. 
GH i  the primary hormone in the fast state; from an evolutio ary po t f view, 
wh n food is scarce, GH c anges fuel consumption from ca bohydrates and pro ein to the 
use of lipids, allowing for th  con rvation f vital protein stores [38]. Huma s’ nitrogen 
balance must be kept stable to ma ntai  th  pool of essential min  acids (EAA) nvolved 
in protein formation. Considering this bal e, differe t EAA ra iolabelling techniques 
h ve been used to evaluate the effects of GH a d IGF-1 o  protein metabolism able 1 
summarises the result  of studies ass ssing prot in anabolism usi g adi isotopes. The 
action of GH on muscle tissue is mainly anabolic and has lit l effect o proteolys s. Still, 
the effects could be differe t depending on the circumstances, dose and ti  of exposition. 
The acute infusion of GH on amino acid metabolism results in  prof und red ction in 
amino acid oxidation [36,37,39–41]. Some st dies demonstrated that acut GH i fusion 
increased wh l -body pr tein yn si  witho t ny significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies usi g higher dos s of GH found lower 
prot olysis rates. In general, acute GH infusion ex rted an anabolic effect on wh le-body 
amino-acid (AA) met bolis , evidenced in re uced leuci e oxidation, increas d n nox-
idative leucine disposal, an increased amino acid disapp arance rate (Rd) (all indexes of 
prot in synthesis) and less fect on protein breakdown (  lower rate of amino acid ap-
pearanc  (Ra)) probably rel ted with dosage  Regardi g ch onic GH exposure, it seems 
more con iste t tha acute administration in pr moting an increase in whole-body pro-
ein synthesis [42–44]. Similar results have been reporte  t  i  pa-
tients with grow h hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisoto es. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resista t type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistan e requires further inv stigation. 
Moreove , GH/IGF1 levels h ve been related to ag ing. In particul r, IGF-1 produc-
ion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 a tions in the muscle h ve structural, metabolic and 
ageing consequ ces and vice ver a. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on uscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, incr ased nonox-
idative leucine dispo al, an increased amino acid di appearance rate (Rd) (all indexes of 
protein synth sis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. egar ing chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in hole-body pro-
tein synthesis [42–44]. Si ilar results have been reported after GH administrati n in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administratio  in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluatin  protein anabolism using radioisotopes. 
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(9.6 μg/kg body ight/d) GH replacement therapy or pl cebo on whol -body glucose 
a d lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatmen  groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resist nt type II X fibres in the 
biop ied muscl s during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and etabolism’s fibre 
typ composition. owever, whether is muscular ibre shift represents the cau e or the 
consequence of in ulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by skeletal muscle is impaired in lder hu ans and inked with aged related sar-
copenia [30]. The ef re, GH/IGF-1 actions in the u cl  ave structural, et bolic and 
ageing consequences and vice versa. 
4.1.  
The ir t reports on the anabolic growth hor one effects dated back to 1948 a d sug-
gest d th t GH inhibits proteolysis during fasting [35]. Subs quent studi s have expanded 
thi  concept [36,37]. 
GH is th primar  horm ne i  t e fast state; fr m an volutionary point f view, 
when ood i  scarc , GH changes fuel consumption from carbohydrates and protein to the 
use  lipids, allowing for th  conservation of vit  r tein stores [38]. Humans’ nitrogen 
b lance must be kept stable to maintain the pool of essential amino acids (EAA) inv lved 
in protein form tion. Cons deri g this balance, different EAA di labelling techniques 
h v  been used to evalu  the ffect  of GH an  IGF-1  protein metabolism. Table 1 
ummarises the r sults o  studi s assessi g prote  anabolism usi g radiois topes. The 
action of GH on muscle tissue is mainly anab lic and has little ffect on proteolysis. Still, 
the effects could be differ nt dep ng on the circumstances, dose an  time of expos tion. 
The acut  infusion of GH o amino ac d metabolism results  a profound reduction in 
amino acid oxi ation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protei  synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, th r studies using higher d ses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted n anabolic effect on whole-body 
ami o-acid (AA) etaboli m, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
pro ein synthesis) and l ss effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. egarding chronic GH exposure, it seems 
more consistent than acut  admi istration in promoting an increase in wh le-body pro-
tein sy thesis [42–44]. Si ilar results have b en reported after GH admini tration in pa-
tients with growth hormone deficie cy (GHD) [45,46], and after GH administration in 
malnourished patient  u der haemodialysis [47].
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replace ent therapy or placebo on whole-body glucos
and lipi  me abolism and muscle composition in 19 GH-deficient adult subje ts. GH ther-
apy result d in glucose metabolism de erioration and an enhanced lipid oxidation rate in 
bot short and long-term t eatment groups, reflecting a fuel use swi ch from glucose o 
lipids. 
Furtherm r , there was a s ift toward m re insulin-resi tant ype II X fibres in th  
b psied muscles d ring GH th rapy. These studies s gnifican ly increased o r 
knowledge rega ding the r lation hip between skeletal muscle a d t lis ’s fibre
type composition. However, wh ther this muscular fib e shift re es nts the cause or the 
consequence of insuli  res ance requires further investigat on. 
Moreover, GH/I F1 levels have been r lated to agei g. In particular, IGF-1 roduc-
tion by th  skeletal muscle is impa re  n old r umans and linked wit  age lated sar-
cope ia [30]. Theref re, GH/IGF-1 cti ns in the muscle have str ctur l, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The fir t reports o  the anabolic growth hormo e effects dated back to 1948 and sug-
gested that GH inhibit  prote lysis uring fasting [35]. Subseq ent studies have expand  
t is c ncept [36,37]. 
GH is th  primary h rmon  in the fast state; from a ev lutio ary po nt of view, 
when food is sc rce, GH changes fuel consum tio  fr m carbohydrates nd pr tein to t  
use f lipids, allowing for the conservatio  of v tal protein s ores [38]. Humans’ n trogen
balanc  must be k pt stable to maintain the pool of es ential amino aci s (EAA) involved 
in protei formation. Consideri g this balance, different EAA r diolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on pr tein metabolism. Table 1 
summarises the results of studies assessing pro ei  anabol sm using rad oisotopes. The 
ac ion of GH on muscle tissue is mainly anabol c and has littl  effect  prote lysis. Still, 
the effect  could be iffere t depending on the circumstances, ose and time of exposition. 
The acute infusion of GH n am no aci  metabolism results in a pr found r ducti  in 
amino acid oxidation [36,37,39–41]. So e studies demonst t d that acute GH inf  
increased whole-body protein synthe is w thout any significant changes i  the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found l wer 
pr t olysis rates. In general, acute GH infusion exerted an anabolic ffect on h le-b dy 
amino-acid (AA) metabolism, evidenc d in r duc d leucine oxidation, increa ed nonox
idative leucine disposal, an increased a ino aci disa pearance ate (Rd) (all indexe of 
protei  synthesis) a d less ffect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more co sistent than cute dmi ist a io  i  pro oting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone d ficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haem dialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first r ports o  the anabolic growth hormon  effect  dated back t  1948 a d sug-
gested that GH inhibits proteolysis during fasting [35]. S bs quent studies have xpanded 
this concept [36,37]. 
GH is t  primary hormone i  the fast tate; from an evolutionary poi t f view, 
when food i  scarc , GH changes fuel con umpti  f om carb hydrates a d protei  to the 
use of lipid , allowi g for the conserv ti  f vital protein stor s [38]. Humans’ nitroge  
balance mu t be kept stable to maint in the pool of esse ti l ami o cids (EAA) i volved 
in protein formation. Considering t is balance, different EAA radiolabelling techniques 
have bee  used to eval ate the ffects of GH and IGF-1 o  protein metab lism. Table 1 
summarises the res lts of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mai l  an bolic a d has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH o  amino aci  metabolism results in a profo d reducti in 
mino acid oxidat on [36,37,39–41]. Some studie  demonstrated that acute GH infusion 
increased whole-body protein synthesis without any sign ficant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In ge eral, acute GH infusion exerted an anabolic effect on whole-body 
amino- id (AA) metabolism, evidenced in reduced leucine oxi ation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all ndexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whol -body pro-
tein sy thesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and ipid metab lis  and muscle compos tion in 19 GH-deficient a ult subjects. GH ther-
apy esulted in glucose metabolism deterioratio  and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resist  type II X fibres in the 
biopsied muscles du ing GH therapy. Th s  studies significantly increased our 
knowledge regarding the r lationship between sk letal muscle and met bolism’s fibre 
type composition. However, wheth r this muscular fibre shift represents the cause or the 
cons qu nce of insulin r sistance r quires further investigation. 
Mor over, GH/IGF1 levels have been related to age g. In particular, IGF-1 produc-
tion by the skeletal muscle is impa red older hu ans and linked with aged relate sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports n the anabolic growth hormone effects dated back to 1948 and sug-
gested hat GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone i  the fast state; from an ev lutionary poin  of view, 
whe  foo  is scarce, GH cha g s fuel co sumption from carbohydrates d protei  to the 
us of lipids, allowing for the conservati  of vital protein stores [38]. Huma s’ nitrogen 
bala ce mus  be kept table to mai t in the pool of essential amino acids (EAA) i volved 
in protein formation. Considering t is balance, different EAA radiolabelling techniques 
have been us d to eval ate the effects f GH and IGF-1 on protein metab lism. Table 1 
summaris the result  of tudies assessing prote  anabolism using radioi otopes. The 
action f GH n muscle tissue is mai ly anabolic and has little effect on prote lysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The ac  infusion of GH o  amino acid m tabol sm results  a profound reduction in 
amino acid oxi ation [36,37,39–41]. Some studie  demonstrated that acute GH infusion 
increa ed whole-bod pro ein synthesis w thout any significant changes in the synthetic 
rate of muscle pr teins. By contrast, other studies using higher doses f GH found lower 
prot olysis rates. In general, acute GH infusion exerted a  an b lic effect on whole-body 
amino-acid (AA) metabolism, videnced in reduced leucin oxidatio , increased nonox-
idative leucine dispo al, an increased amino acid di a earance rate (Rd) (all dexes of 
protein ynthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dos ge. R gar i g hronic GH expo ure, t seems 
more consistent than acute admi istration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Si ilar r sults have been reported after GH ad inistration i  pa-
tients with growth hormon  deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluati g protein anabolism using radioisotopes. 
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(9.6 μg/kg body w ight/d)  eplacement therapy or p acebo on whole-body glucose 
and lipid meta lism and mus le composition in 19 GH-deficient adult subjects. GH ther-
apy resulte  in glucose metabolism deteriorati  a d an enhan ed lipid oxidation rate in 
both short and lon -term treatment groups, reflecting a fuel use switch from gluc se to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantl  increased our 
knowledge regarding the relationship betw en skeletal uscle a d metabolism’s fibre 
type c mposition. However, whether t is muscular fibre shift repr se ts th  cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have b en related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older hu ans and linked with aged related sar-
copenia [30]. Th r fore, GH/IGF-1 actions in th  scle h ve structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The fi st reports on the nabolic growth horm ne effects dated back o 1948 and sug-
gested that GH inhibits proteol sis durin  fasting [35]. Subsequent stu es hav  expa ded 
this oncept [36,37]. 
GH is the primary hormone in he fast st te; from  evolutionary point of view, 
whe  f  is c rce, GH ch nges f el c nsumption from carbohydrates a d protei  t  the 
use of ip ds, allowing for the co se vation of vital protei  stores [38]. Humans’ nitrogen 
balance mu t be kept stab  to mai tain the p l of e nti l min  acids (EAA) involv d
n formation. Considering his b lance, different EAA radiolab lling techniques 
h v  b en used to eval at  t e ffects f GH and IGF-1 o  prote n met oli m. Tabl  1 
su maris s the results of s udies a se sing protei  anabolism using radioisot pes. he 
acti  of GH on muscle ti s e is mainly anabolic and has little ffect o  prote lysis. Still, 
the effects could b  different dep nding on the circumstances, os  and time of exposi i . 
The cute infusion of GH on amino acid metabolism results in a profoun  r duction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated th t acute GH inf sion 
increas d whole-body protein synthesis without any signific nt chang s in the synthetic 
rate of muscle pr t ins. By c ntrast, ot r studies sing hi her doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted a  anabolic eff ct on whole-body 
mino-acid (AA) metab lism, evide ced in reduced leucine oxidation, increased nox-
idativ  leucine disposal, n increased amino acid di a p ara ce rate (Rd) (all ind xes of 
protein synthesis) and le s effect on protein bre kdown (a lower rate of amino aci  ap-
pearanc  (Ra)) robably related with dosage. Regarding chronic GH exposu e, it ems 
more consisten  tha  acute administration in promoting an increa e in whole-bo y pro-
tein synthesis [42– 4]. Similar results have b en reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], an  ft r  a minis ratio  in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/k  body weight/ ) GH replacement therapy or plac bo on whole-body glucose 
nd lipid metabo ism and musc e compos tion i  19 GH-d ficient adult subjec s. GH ther-
apy resulted in glucos  abolism deterioration and an enha c d l pid oxidation rat  in 
both hort and long-term treatment groups, reflecting a fuel se switch from glucose to 
lipids. 
Furthermor , the e was a hift toward more ins l n-resistant type II X fibr s in the 
bi psied muscle  during GH t erapy. These tudies ignificantly increased our 
knowledg  regarding the relationship betw en skeletal muscl  and metabolism’  fibr  
type compositio . How ver, wh ther this musc lar fibre shift rep sents the cause or the 
consequ nc  of insulin resistance requir s furth r investigatio . 
Mor v r, GH/IGF1 levels h v  been r lat d to agei g. I  particul r, IGF-1 produc
ti n by the sk letal muscle is i paired  older u ans d linked with aged r lat d sar-
cope ia [30]. Ther fore, GH/IGF-1 actions i  the muscle have structural, metabolic and 
ageing consequ nc s and vice versa. 
4.1. GH 
The first r ports on th  anabolic gro t  hormon effects dated back to 1948 a d sug-
gested that GH inhibits proteolysi  during fasting [35]. Subsequ nt studies h ve expand d 
this con ept [36,37]. 
GH is the prim r ormone i  the fast at ; fro  n evolution ry oi  of view, 
wh n fo  i  scarce, GH ch ges fu l consum tion f m c b hydrates a d protein t  the 
use of lipids, allo ing for the co s rvation of vital p otein sto s [38]. Hu a s’ itrogen
balanc  must be kept stable o maint the pool f ss ial mino acids (EAA) i vol ed
in rot  form ion. Consi ri g h bala ce, ifferent EAA radiolabelling techn qu s 
have b en us d to ev lu te th  ffect  of GH and IGF-1 on protei  m tab lism. Table 1 
summari es the result  of t dies as e sing protei  a bolism using radiois tope . The 
action of  on muscle tissu  is a ly anaboli  and h s little effect on pr teolysi . Still,
t effec s co ld be d ferent pe di g on the circu stance , dose and tim of expositi .
T e acu e infu ion f GH on amino acid metabolism resul  n a rofo nd reduction i  
amino acid oxi ation [36,37,39–41]. Some studies de o str ted t t acute GH i fusion 
increased whole-body protei  synthesis without any sign ficant changes in the synthetic 
rate f mu cle proteins. By contrast, other tudies using hi er dos s of GH found lower 
prote lys s rates. In general, acute GH infusion ex rted a  a abolic effect n whole-b dy 
am no-acid (AA) met bolism, evide c d  reduced l ucine oxid ion, increase  ox-
idative leucin  dispo al, an increased ami o acid isappearance at  (Rd) (all indexes of 
rotei  synthe is) and less ffect on protein br akdown (a l wer rat  of amin acid a -
pea ance (Ra)) p obably r l t d w th d sage. R gard chronic GH exposure, it seems 
more c nsi t nt than acute adminis ration in prom ting n increase in whole-b dy ro
t i  syn esis [42– 4]. Similar r sult  have been reported after GH ad inistration  pa-
tients wit  grow h hormone d ficiency (GHD) [45,46], and after GH administration i  
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studie  with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterior tion and a  enhanced lipid oxidation rate  
both short and long-term tre tment groups, reflecting a fuel use swit h from gluco  to 
li ids. 
F rtherm re, there was a shift toward more insulin-resistant typ  II X fibres in the 
biopsied mus les during GH th rapy. Th se studies significantly increased our 
knowledge garding th  relation ip between sk le al muscl  and metabolism’s fibre 
ty  composition. However, whether this muscular fibr  shift represents e c use or the 
conseque ce of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels ha  been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is i paired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on t e anabolic growth hormon  e fects dat d back to 1948 a d sug-
gested that GH inhibits prot olysis during fasting [35]. Subsequent studies h ve expanded 
this concept [36,37]. 
GH is the primary hormo e in the f st state; from an evolutionary point of view, 
wh  food is sca ce, GH changes fuel c nsumption from carbohydrates and protein to the 
se of lipids, allowing f r the cons rvation of vital protein st res [38]. Humans’ nitrogen 
bala ce ust be kept stable to maintain the p l of essenti l a in  acids (EAA) inv lved 
in protei  formation. Consi ring this ba ance, different EAA radiolabelling techniques 
have been used to evaluat  the effects of GH and IGF-1 on protein metabolism. Table 1 
summ rises the re ults of st dies assessing protein a aboli m using radi isotopes. The 
action of GH on muscle tissue is mainly anabolic and ha  little effect n proteolysis. Still, 
th  effects could be different dependi g on the circ mstances, dose and time of exposition. 
The cute inf s o  of GH on ami o acid m tabolism results in a pr foun  reduction in 
a ino id oxid ion [36,37,39–41]. Some stu ies emonstrated that acut  GH i fusion 
increased whole-body protein synthesis without any signifi a t changes in the synthetic 
rate of muscl  proteins. By co trast, other studies using high r dos s of GH found lower 
proteolysis rates. In genera , acute GH infusion xerted an anabolic ffec   whole-body 
a o-acid (AA) met olism, evidenc d in reduced leuci e oxidat o , creased nonox-
idative l uci e disposal, an increased amino acid di appearance rat  (Rd) (all ind xes of 
prot i  i ) and less ffect on protein breakdown (a low r rate of a ino c d ap-
pearance (Ra)) p bably related with dosage. Regarding chronic GH exposure, it seems 
ore consistent than acute administr tion in promoting an increase  whole-body pro-
tein sy hesis [42–44]. Simil r results have been reported fter GH dministration in pa-
tients wi h growth ormone deficie cy (GHD) [45,46], and after GH administration in 
malnourished patie ts under haemodialysis [47]. 
Table 1. Most relev nt studi s with GH evaluating protein a abolism using radioisotopes. 
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(9.6 μg/kg body w ig t/d) GH repl cement thera y or placebo on whole-body glucose 
nd lipid metabolism  mu cl  composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose etabolis  deterioration and an enhance  lipid xidation rate in 
both sh rt and long-t rm treatment gr ups, reflecting a fuel use switch from glucose to 
lipids. 
Further ore, there was a shift toward more insuli -r sista t type II X fibres i  the 
bio sied muscl s duri g GH therapy. Th se studies sig ificantly i creased our 
knowledge regardi g the relationship between skeletal muscle and metab lism’s f bre
typ  co po ition. However, wh th r this muscular fibre shift repres nts the cause or e 
conseque ce f ins lin r sistance q ires further i vestigatio . 
Moreover, GH/IGF1 l vels have bee  related to ageing. In p rticular, IGF-1 r duc-
tion by th  sk letal muscle is impaired in ld r humans and linked with aged relate  sar-
cope ia [30]. Therefore, GH/IGF-  actions i  th  muscle have s ructural, metabolic a d 
ag ing co sequ nces a  vice vers . 
4.1. GH 
The f rst reports on the an b lic growth hormone ffects dated back to 1948 and ug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have xpanded 
this co cept [36,37]. 
GH is the im ry h rmone in the f st state; from an evolutionary point of vi w, 
when food i  scarce, GH changes fuel co s mption from c rbohydrates and protein to the 
use of lipi , allowing for the conservation of vital ro in sto es [38]. Humans’ nitrogen 
balanc  must be ke t stable to ma ntai  the pool of essenti l mino acids (EAA) involved 
in protein formation. Co sidering this bala ce, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein a abolism using radioisotopes. The 
action of GH on muscle tissue is mainly ana olic and has little effect on prote lysis. Still, 
th  effects could be different dependi  on the circumstances, dose and time of exp sition. 
The ac te infusion of GH on amino acid metabolism results in a profo nd reduc ion in 
amino acid oxidation [36,37,39–41]. Some studies d monstrated that acute GH infusion 
increased whole-body pr tein synthesis without any significant changes in the synthetic 
rate of muscle protei s. By c trast, other studies using higher doses of GH found lower 
proteolysi  rates. In general, acute GH infu ion exerted an anabolic effect on whole-body 
mino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (al  ind xes of 
protein synthesis) and less effect on protein breakdown (a low r rate of mino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more co istent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Si ilar results have been reported after GH admi istration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after H admi istr tio  n 
malnourished patients under haemodialysis [47]. 
Table 1. Most rel vant studies with GH evaluating protein anabolism using rad oisotopes. 
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(9.6 μg/kg body weight/d) GH replacement th rapy or placebo on whole-body glucose 
and lipi  metabolis  and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deteriorati n and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift oward mor  in ulin-resistant type II X fibres in the 
biopsied muscl s during GH therapy. These studies significantly increased our 
knowledge regarding the relationship bet een skel tal muscle and metabolism’s fibre 
type composition. However, whether thi  muscular fibre shift represents the cause or the 
consequenc  of insulin resistance requires further investi ation. 
Moreover, GH/IGF1 levels hav  been related to ageing. In particular, IGF-1 produc-
tio  by the skeletal muscl  is impaire  in older humans and linked with aged related sar-
c p ni  [30]. Therefore, GH/IGF-1 acti ns in the uscl  have structural, metabolic and 
ageing con equences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
whe  food is scarce, GH changes fuel consumption fro  carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance ust be k pt stable to maintain the pool of essential amino acids (EAA) involved 
in protein for atio . Considering this balance, different EAA radiolabelling techniques 
hav  been used to evalu te the effects f GH and IGF-1 on protein metabolism. Table 1 
sum rises the results of studies a ses ing protein anabolism using radioisotopes. The 
actio  of GH on muscle tissue i  mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on th  circumstances, dose and time of exposition. 
The acute infu ion of GH  amino acid metabolism re ults in a profound reduction in 
amino acid oxidation [36,37,39–41]. So e studies demonstrated that acute GH infusion 
increased whole-body protein synthe is without any significant changes in the synthetic 
rate of muscle proteins. By contr st, other studies using higher doses of GH found lower 
proteolysis rates. In g n ral, acute GH infusion exerte  an anabolic effect on whole-body 
a ino-acid (AA) metabolism, evid nced in reduced leuc ne oxidation, increased nonox-
idative leucine disposal, an increased am o cid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
m re co sistent than ac te administration  om ting an increase in whole-body pro-
t in synthesis [42–44]. S milar results hav  be n reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under hae odialysis [47]. 
T ble 1. Most relevant stud es with GH evaluating prote anabolism using radioisotopes. 
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(9.6 μg/kg body w ight/ ) GH replacem nt therapy r lacebo on wh le-body glucose 
and lip d metab lism nd mu cl  comp siti n i 19 H-deficie  ad lt su jects. GH th r-
apy result in glucose metabolism d teri ration a d an enhan ed li id oxidati n rate in
both h rt and long-term treat nt groups, reflecti g  fuel use switch r m glucose to 
lipids.
F rtherm e, ther  w s a shift towar  insuli -re istant typ II X fibres i  the 
biops ed muscl s during GH therapy. Th se st di  signific ly incre se  our
kn wl dg egarding th  rel tio ship be ween skel tal muscl  and metabolism’s ibre
ype co po itio . However, whet er t m scular fibre shift repr ents the caus  or the 
c s quence of insulin resist nce r quires fur h r vestigat on. 
Mor over, GH/I F1 level  have been related to agei g. In p rtic lar, IGF-1 duc
i  by t k l al muscl is mp i ed lder huma s nd l ke with aged relat d ar-
c pe ia [30]. Theref , GH/IGF-1 acti s in th  mus le have struc ural, e abol c and 
agei g c nsequ ces and vice v s . 
4.1. GH 
T e firs  r ports on the anabolic growth hor one effects dat d back to 1948 and sug-
gested that GH inhi its proteolysis during fasting [35]. Subsequent studies have xpanded 
this concept [36,37]. 
GH is the primary hormone in t e fast state; from an evolutionary poin  f view, 
when food is scarce,  changes uel consumption from c rbohyd tes and protein t  the 
use of lip ds, allowing for the conservation of vital protein stores [38]. Humans’ itrogen 
bala ce must be kept stable to m in ain the pool of e sential amino acid  (EAA) involved 
in protein formation. Considerin  this bala ce, diff rent EAA radi labelling techniques 
ave been used to eval ate the effects of GH and IGF-1 on protein etabolism. Table 1 
summar ses t  results of studies as e sing protein an bolism using radioisotopes. The 
action of GH o  muscle tissu  is mai ly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose nd tim  of xposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acut GH infusion 
increased whole-body protein synthesis without any significa t changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteoly s rates. In general, acute GH infusion exerted an anabolic effe t on whol -body 
amino-acid (AA) metabolism, ev denced in reduc d leucine oxid io , incre sed nonox-
idative leucine disposal, an increased amino aci disappearance r  (Rd) ( ll ind xes of 
protein synthesis) and l s effect on protein breakdown (a lower rate of amino acid ap-
pear nc  (Ra)) pr bably related with dosag . g rding chronic GH expo ure, it seems 
more onsist nt tha  ac te administration in promoting an incre se  whole-body pro-
tein synthesis [42–44]. Similar results hav  been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body gluc se 
and lipid metabolism and muscle composition in 19 GH-def cient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid ox dation rat in
both short and long-term treatment groups, reflecting a fuel use swit h fro  glucos  t  
lipids. 
Furthermore, there was a shift toward more insulin-res stant ype II X fibres n th  
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been elated to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged lated sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 an  sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view,
when food is scarce, GH changes fuel consumption from carbohydrates and protein to t e 
use of lipids, allowing for the conservation of vital protein stores [38]. Human ’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein me ab li m. Table 1 
summarises the results of studies assessing protein anabolism using rad oisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on th  circumstances, dose and time of xposition. 
The acute infusion of GH on amino acid metabolism results in a profound reductio  in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in t e synthetic
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in educed leucine oxidation, incre sed nonox-
idative leucine disposal, an increased amino acid disappe r nce rate (Rd) (all i d xes of 
protein synthesis) and less effect on protein breakdown (a lower rat  of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole- ody glucose 
and lipid metabolism and muscle composition in 19 GH-defici nt adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an en nced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switc  from gluc se to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the
biopsied muscles during GH therapy. Thes  studies sig ificantly inc eased ur 
knowledge regarding the relationship between skeletal m scle and metabolism’s fibr  
type composition. However, whether this muscular fibre shift r pre e s the c se or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particul r, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and li ked with ed r l ted sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have struc ral, m tab lic a d
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic gr wth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subs que t stu ies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary poin  of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and rotei to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) invol ed 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using adio sotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on p o olysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid etabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated t t cute GH infusion 
increased whole-body protein synthesis without ny significa t changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein br kdown (a lower rate of a ino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it eems 
more consistent than acute administration in promoting an increase in whole-b dy pro-
tein synthesis [42–44]. Similar esults have been reported after GH administration i  pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whol -body glucose 
and lipid metabolism and muscle composition in 19 -deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidatio  rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant ype II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metaboli m’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or t e 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 pr duc-
tion by the skeletal muscle is impaired in older humans and linked with ag d r l ted sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1.  
The first reports on the anabolic growth ho mone ffects dated back t  1948  sug-
gested that GH inhibits proteolysis during fasting [35]. Subseq nt studi s have expande  
this concept [36,37]. 
GH is the primary hormone in the fast state; fr m an evolution ry p int of ew, 
when food is scarce, GH changes fuel consumption fr m carbohydrate  and protein to t  
use of lipids, allowing for the conservation of vital pr t in s ores [38]. Humans’ nitr ge  
balance must be kept stable to maintain the pool of sse tial min  ci s (EAA) i volve  
in protein formation. Considering this balance, iffer t EAA radi labell ng t chniques 
have been used to evaluate the effects of GH and IGF-1 o  pr tein metabolism. Table 1
summarises the results of studies assessing pro ei  abolism usi g radiois topes. The 
action of GH on muscle tissue is mainly anabolic and has little ffect on proteolysis. St ll, 
the effects could be different depending on the circumst c , o e and ti  of expositi n. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–4 ]. Some studies demo strated that acute GH infusion 
increased whole-bod  protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using high r doses f GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid di appearance rate (Rd) (all in exes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting  increase in whole-body pro-
tein synthesis [42–44]. Similar esults hav  been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administratio  in 
malnourished patients under haemodial sis [47]. 
Table 1. Most relevant studi s with GH evaluati g protein anabolism using radioisotopes. 
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not change. Ins: insulin, Leu: leucine, Ox: oxidation, BCAAs: branc d-chain amino acids, Phe:
phenylalanine, NW: normal weight, OB: obese, wk week. Units: Kg: kilogram, h: hours, IU: international units, min: minutes, mg:
milligram, mU: primary units, µg: microgram. Rd: (Phe/Leu disappearance rate) represents protein synthesis. Ra: (rate of appearance of
Phe/Leu) represents proteolysis. Hypopit: hypopituitarism. Ox—oxidation.
Norreland et al. (2001) [48] evaluated the action of GH on fasting longer than overnight.
They found that GH suppression led to increased proteolysis and with GH replacement
they found a significant decrease in branched-chain amino acid levels, consistent with
decrease proteol sis.
Nevertheless, in studies designed to recover the muscle loss in the elderly, the over-
all impact of GH administration has been far lower than expected [44,49,50]. Little is
known about GH uses in fitness [51]. However, recently, in patients in need of reparative
knee surgery Mendias et al. (2020) [52] found that rhGH compared to placebo improved
quadriceps strength and reduced MMP3 (a subrogated marker of cartilage degradation).
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Altogether, these experiments support the anabolic action of GH with less effect on
proteolysis, depending on time length and the context of GH exposition. These effects
probably become more evident with more prolonged GH exposure or in a pathological
state as acromegaly accompanied by elevated insulin and IGF-I levels.
4.2. IGF-1
IGF-1 is one of the most important signals in muscle anabolism and repairs [30,53,54].
As mentioned above, IGF-1 is secreted by the liver after GH stimuli and directly from
skeletal muscle in an autocrine/paracrine manner [33]. IGF-1 mediates beneficial outcomes
of physical activity [55] and can prevent chronic disease [56].
The first reports of IGF-1 date back to 1957 as “sulphation factor”, when Salomon et al.
described its ability to stimulate 35-sulphate incorporation into rat cartilage. Later, IGF-1
(called somatomedin-C) was assumed to be a mediator of anabolic and mitogenic GH
activity [57], but this concept drastically changed after verification of the local production
and action of IGF-1 [33,58].
Immediately after IGF-1 biosynthesis [59], a new challenge in clinical research was
opened up. First, Guler et al. (1987) [60] compared eight healthy adult volunteers, the short-
term metabolic effects of IFG-1 and insulin. Next, Laron et al. (1990) [61,62] investigated
IGF-1 impact on GHRH in healthy adults and children with primary IGF-1 deficiency (GH
insensitivity) or Laron’s Syndrome (LS). Laron et al. were also the first to introduce the
long term administration of biosynthetic IGF-1 in LS [63,64]. Some of the most relevant
studies in humans, with systemic IGF-1 administration and its impact on protein and the
muscular system, is summarised in Table 2.
Table 2. Most relevant studies in humans, with systemic IGF-1 and muscle actions.
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is he primary hormo e in the fast state; from an evolutionary point of view, 
when food is scarce, GH ch nges fuel consumption from ca bohydrates and protein to the 
us  of lipids, allowing for the conservation of vital pr tein stores [38]. Humans’ nitrogen 
bal ce must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balanc , different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studi s with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased amino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein ynthe is [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the m scle hav  structural, metabolic and 
ageing consequences and vic  v rsa. 
4.1. GH 
The first reports on the anabolic growth hormone effects dated back to 1948 and sug-
gested that GH inhibits proteolysis during fasting [35]. Subsequent studies have expanded 
this concept [36,37]. 
GH is the primary hormone in the fast state; from an evolutionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Humans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balance, different EAA radiolabelling techniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolism. Table 1 
summarises the results of studies assessing protein anabolism using radioisotopes. The 
action of GH on muscle tissue is mainly anabolic and has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and time of exposition. 
The acute infusion of GH on amino acid metabolism results in a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that acute GH infusion 
increased whole-body protein synthesis without any significant changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found lower 
proteolysis rates. In general, acute GH infusion exerted an anabolic effect on whole-body 
amino-acid (AA) metabolism, evidenced in reduced leucine oxidation, increased nonox-
idative leucine disposal, an increased a ino acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on protein breakdown (a lower rate of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replacement therapy or placebo on whole-body glucos  
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deterioration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-r sistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shift represents the cause or the 
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 actions in the muscle have structural, metabolic and 
ageing consequences and vice versa. 
4.1. GH 
The first reports on the anab lic growth hormo e effec s d ted back to 1948 and sug-
gested that GH inhibits pro eolysis during fasting [35]. Subsequent studies hav  expanded 
this concept [36,37]. 
GH is the primar  hormone in the f st st te; from an evo utionary point of view, 
when food is scarce, GH changes fuel consumption from carbohydrates and protein to the 
use of lipids, allowing for the conservation of vital protein stores [38]. Hu ans’ nitrogen 
balance must be kept stable to maintain the pool of essential amino acids (EAA) involved 
in protein formation. Considering this balanc , different EAA radi labelling t chniques 
have been used to evaluate the effects of GH and IGF-1 on protein metabolis . Table 1 
summarises the results of studies assessing protein an bolism using r dioisotopes. The 
action of GH on muscle tissue is mainly anabolic n  has little effect on proteolysis. Still, 
the effects could be different depending on the circumstances, dose and tim  of expos ti n. 
The acute infusion of GH on amino acid metaboli m results i  a profound reduction in 
amino acid oxidation [36,37,39–41]. Some studies demonstrated that cute GH infusion 
increased whole-body protein synthesis without a y ig ific t changes in the synthetic 
rate of muscle proteins. By contrast, other studies using higher doses of GH found low r 
proteolysis rates. In general, acute GH infusion exerted an nab lic eff ct on whole-body 
amino-acid (AA) metabolism, evidenced in reduced l ucine oxidation, increased nonox-
idative leucine disposal, an increased ami o acid disappearance rate (Rd) (all indexes of 
protein synthesis) and less effect on pr tein breakdown (a lower r te of amino acid ap-
pearance (Ra)) probably related with dosage. Regarding chronic GH exposure, it seems 
more consistent than acute administration in promoting an increase in whole-body pro-
tein synthesis [42–44]. Similar results have been reported after GH administration in pa-
tients with growth hormone deficiency (GHD) [45,46], and after GH administration in 
malnourished patients under haemodialysis [47]. 
Table 1. Most relevant studies with GH evaluating protein anabolism using radioisotopes. 
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(9.6 μg/kg body weight/d) GH replaceme t therapy or placebo on whole-body gl cose 
and lipid metabolism and muscle composition in 19 GH-deficient adult subjects. GH ther-
apy resulted in glucose metabolism deteri ration and an enhanced lipid oxidation rate in 
both short and long-term treatment groups, reflecting a fuel use switch from glucose to 
lipids. 
Furthermore, there was a shift toward more insulin-resistant type II X fibres in the 
biopsied muscles during GH therapy. These studies significantly increased our 
knowledge regarding the relationship between skeletal muscle and metabolism’s fibre 
type composition. However, whether this muscular fibre shif  represent  the cause or the
consequence of insulin resistance requires further investigation. 
Moreover, GH/IGF1 levels have been related to ageing. In particular, IGF-1 produc-
tion by the skeletal muscle is impaired in older humans and linked with aged related sar-
copenia [30]. Therefore, GH/IGF-1 action  in the musc e have structural, metab lic and 
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In healthy people, Clemmons et al. (1992) [65] found evidence that short term IGF-1
infusion, was able to reverse fasting diet-induced muscular catabolism. There is also some
evidence indicating that the effects of the systemic administration of IGF-I on protein
metabolism depend on environmental AA levels. In this regard, Turkalj et al. (1992) [66]
showed that IGF-I administered without AA, suppressed proteolysis, while in the study by
Russell-Jones DL, et al. (1994) [67]. IGF-1 administration in combination with AA infusion
increased protein synthesis. Likewise, Kupfer et al. (1993) [68] found that GH and IGF-1
anabolic effects were enhanced when co-administered in 7 healthy calorically restricted
patients. Lagger et al. (1993) [69], compared high and low doses of rhIGF-1 and found that
high doses of IGF-1 decreased proteolysis more than insulin. However, it was accompanied
by an unexpected inhibition of protein synthesis.
More recently, some researchers have studied the effects of rhIGF-1 on muscle perfor-
mance in special populations. Rutter et al. (2020) [70] investigated 21 boys with Duchenne
muscular dystrophy and found that after 6 months of rhIGF-1 therapy, despite improve-
ments in linear growth, muscular motor function did not change. Guha et al. (2020) [71]
studied fifty-six recreational athletes and observed that muscular aerobic performance
improved after 28 days of rhIGF-1/rhIGFBP-3 administration, but no effects on body com-
position. It should be taken into account that circulating IGF-1 is probably less important
in those tissues that can produce the hormone themselves, such as skeletal muscle [72]
Focusing on ACRO, some degree of IGF-I receptor resistance to IGF1 action has
recently been reported [73]. This important finding could explain why in the presence of
high IGF1 levels, the metabolic GH effects are predominant in these patients. In addition,
IGF-1 resistance might also be involved in other ACRO related muscle disturbances.
In summary, these data suggest that the administration of IGF-1 inhibits proteolysis
and improves muscle performance with less effect on protein synthesis. Other factors such
as local IGF-1 secretion and/or IGF1R resistance could play an important role. The data is
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still controversial, and the combined and additive effect of IGF-1 and GH co-administration
remains a subject of debate.
5. The Key of mTOR in Muscle Structural and Metabolic Function
Skeletal muscle mass and whole-body metabolism are closely related. One of the
major players in coordinating growth with nutrient availability is rapamycin’s mammalian
target (mTOR) [74]. There are two different mTOR complexes, mTORC1 and mTORC2.
In brief, mTORC1 senses nutrients, oxygen, energy, and growth factors promote cell
growth, regulates metabolic processes, and mTORC2 responds more specifically to growth
factors and regulates cell survival and metabolism [75]. Specifically, mTORC1 plays a
key role in muscle structure, stimulating postprandial and post-exercise muscle protein
synthesis. This pathway is mainly activated by mechanical contraction (i.e., exercise),
which causes paracrine IGF-1 secretion [72]. However, AA intake also participates in
governing the mTORC1 pathway. It has been shown that leucine is a potent stimulator of
muscle protein synthesis by triggering mTORC1 signalling in human skeletal muscle [76].
Recent work has found that during AA sufficiency, mTORC1 kinase activity is stimulated
mainly in 3 ways: (1) The lysosomal AA transporter SLC38A9 sensing arginine within the
lysosome [77]; (2) The leucine sensor Sestrin2 [78]; (3) The arginine sensor [cellular arginine
sensor for mTORC1 (CASTOR1)] [79]. All these pathways ultimately allow mTORC1 to be
activated (Figure 3).
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Figure 3. The interplay of GH, IGF-1, insulin, hybrid receptor and nutrients in the muscle. Schematic and simplified
signalling pathway and the interplay of GH, IGF-1, insulin, hybrid receptor and nutrients in the muscle. AA (amino-acid)
stimulates mTOR kinase activity mainly in 3 ways: (1) The leucine sensor Sestrin, (2) the lysosomal sensor SLC38A9,
(3) The arginine sensor [cellular arginine sensor for mTORC1 (CASTOR1)]. GH activates via IRIS and SHC protein and
mitogenic effects as well as IGF-1R/InsulinR and HybridR. GH also stimulates via JAK/STAT local muscular IGF-1
secretion. In addition, the metabolic effects of GH impact on muscle anabolism. The main metabolic action of GH is a
lipolytic action on adipose tissue, releasing free fa ty acids (FFA), which favours protein preservation, as well as liver and
kidney-enhanced gluconeogenesis.
Similarly to IGF-1R resistance described in ACRO, an “anabolic resistance” due to
an impairment of the “sensor” capacity of the muscle to metabolise circulating AA has
been related to the sarcopenia that occurs in the el erly [76]. This reduced ability is
probably associated with impairments in molecular signalling such as decreased amino
acid transport, which results in reduced mTORC activation.
Int. J. Mol. Sci. 2021, 22, 415 10 of 18
Recently, we have reported low circulating levels of branched-chain amino acid in
active ACRO [80]. This finding could contribute to the myopathy observed in patients with
ACRO, but further basic and clinical research on this issue is needed. In this regard, to the
best of our knowledge, there are no studies addressed to investigate the potential role on
muscle performance of diet enriched with AA in ACRO.
6. Impact of GH/IGF-1 Axis Impairment on Muscle Metabolism and Function: Lessons
from Basic Research
The GH and IGF-1-mediated regulation of skeletal muscle structure and performance
have recently been reviewed [54,81,82]. We will focus on the impact on the muscle of
diseases with low or excess GH/IGF-1.
6.1. Primary Cell Cultures
In vitro studies using immortalised the mouse myoblast cell line C2C12 has provided
preliminary evidence regarding the action of IGF-I in muscle stimulating muscle protein
synthesis, and also in suppressing proteolysis [83]. IGF-1 is also related to myoblast
proliferation [84] and differentiation [54]. In addition, IGF-1 modulates the expression of
L-type amino acid transporters in the muscles of spontaneous dwarf rats [85].
Mahendra et al. (2010) [86], in an elegant work using cell lines of mice lacking either
the GH receptor or the IGF-1 receptor in skeletal muscle, found that GH mediates skele-
tal muscle development by enhancing myoblast fusion in an IGF-1-dependent manner.
They showed that GH treatment quickly increases IGF-1 mRNA and that this autocrine
production of IGF-I leads to a significant increase in primary myoblast proliferation. By con-
trast, disruption of the GH receptor in skeletal muscle produces marked alterations in
muscle nutrient uptake and insulin sensitivity in an IGF-1-independent manner.
Altogether, these findings indicate that the myoblast anabolic process is a complex
action where both hormones are complementary. Nevertheless, metabolic dysfunctions
seem to be more related to GH impairment.
6.2. Transgenic Mice
Several genetically modified animal models (giants and dwarfs) have been gener-
ated and characterised in the last 30 years [87–89] and have been used to investigate the
phenotype, consequences and mechanisms underlying the altered GH/IGF-1 axis [90]
This review will focus on the most relevant ones: transgenic mice overexpressing GH
and GH knockout mice. For comprehensive reviews, please see references [87,91–93].
High GH levels in transgenic mice have elevated GH and IGF-1 levels, increased
body weight, and lean mass. The extreme elevation in circulating GH also results in
hyperinsulinemia despite euglycemia, probably due to reduced insulin receptors or GLUT4
channels in skeletal muscle. There are some differences among the various GH transgenes
species in mice (e.g., ovine GH, bovine GH or human GH). Human GH can bind to both GH
and prolactin (PRL) receptors, whereas rat, bovine and ovine GH bind exclusively to GHR.
Thus, overexpression of human GH in mice results in a physiological state in which both
GH and PRL receptors are simultaneously activated in contrast with rat, bovine, or ovine
where only GHR is activated [92]. Together with the different ages of the mice used in the
experiments, these differences could explain the heterogeneity of the published results
regarding body composition. Besides, the following aspects should be taken into account
when using transgenic mice: (1) In ACRO, GH secretion is from a pituitary adenoma
whereas, in GH transgenic mice, GH excess is due to transgene insertion resulting in
ectopic GH secretion. (2) The level of circulating GH is often markedly greater in transgenic
mice than is observed in ACRO. (3) Transgenic mice exposure to excessive GH begun
immediately after birth mimics gigantism more than ACRO (4) in human transgenic mice,
GH and PRL receptors are simultaneously activated, unlike in ACRO.
In complete contrast to high GH level transgenic mice, there are the dwarfism models:
The GH knockout mice (GHKO or GH−/−), completely lack GH due to a targeted deletion
of the GH gene. These mice represent a model of human isolated GH deficiency. The GH
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receptor gene disrupted mice (GHR−/−) are mice completely resistant to GH action;
they also have a pronounced decrease in body size with extremely low circulating IGF-1 de-
spite elevated GH levels and constitute the model for LS. Other types of dwarfism models
are transgenic IGF-1 knockout mice. Although the animals are born alive, mortality rates
range from 32% to 95% due to respiratory failure caused by impaired diaphragm develop-
ment, severe muscle dystrophy and intercostal muscles. These mice also develop metabolic
abnormalities such as mild hyperglycaemia (250 mg/dl) and decreased pancreatic beta
cells [63,94].
Finally, another model of IGF-1 deficiency is a consequence of a deletion of the gene
encoding the IGF-1 in the liver (only in the liver, not in other tissues), resulting in a 75%
reduction of circulating plasma IGF-1 levels [95]. These animals usually grow and are
fertile. It has been suggested that high levels of growth hormone and increased paracrine
or tissue IGF-1 levels compensate for the lower plasma levels of IGF-1.
Overall, these findings provide evidence that both GH and IGF-1, including locally
muscular secreted IGF-1, have active implications for growth and muscle development.
6.3. Experimental Research Focused on the GH/IGF-1 System Effects on Muscle
The effects of GH deficiency in muscle have been controversial. Ayling et al. (1989) [96]
reported a 50% reduction in type I fibres after rat hypophysectomy, that recovered after GH
therapy. Similar results were obtained by Loughna and Bates five years later (1994) [97].
By contrast, Yamaguchi et al. (1996) [98] also observed a significant increase in type I fibres
after rat hypophysectomy. Some studies have also reported no change in the composition
of type I or type II fibres after GH replacement in the same experimental model [99].
These divergent results could be explained by the different exposure to GHD, GH therapy
duration, and the associated deficit of other hormones such as thyroxine, testosterone
and glucocorticoids.
Nielsen et al. (2014) [100] in an elegant work, measured the ultra-structure and
collagen in the Achilles tendon, employing three groups of mice: (1) Giant transgenic
mice that expressed bovine GH (bGH): the ACRO model; (2) Dwarf mice disrupted GH
receptor GHR−/− (the LS model) and (3) A wild-type control group. They found that
the mean collagen fibril diameter was significantly decreased in the ACRO and LS models.
The ultra-structural pattern was more severely affected in the GHR−/− mouse model.
Similarly, a recent study of Cinaforlini et al. (2020) [101] investigated muscle repair
and found that GH administration accelerated the muscle healing process.
Regarding the direct effect of IGF-1 on the muscle, Schoenle et al. in 1982 [102]
reported that IGF-1 stimulated growth in hypophysectomised rats, thus providing evidence
of independent IGF-1 action from GH. DeVol et al. in 1990 described for the first time
the local skeletal muscle production of IGF-1 [58]. Using a rat model of compensatory
hypertrophy of the soleus, the authors showed that muscle hypertrophy and local IGF-1
production occurred independently of GH. However, compensatory hypertrophy was not
blunted in hypophysectomised rats.
All this evidence reinforces the concept that although the actions of GH and IGF1 in
the muscle, are independent, they are complementary.
7. The Muscle in GH/IGF1 Axis Deficiency
Isolated GH deficiency (IGHD) either congenital or acquired, is the commonest pi-
tuitary hormone deficiency [103]. First description and treatment date from 1963 [104].
During childhood and puberty, the classical phenotype of GHD is short stature with height
≤ −2 SDS, frontal bossing, mid-facial hypoplasia (“doll-like” facies) and truncal adipos-
ity [105]. Adult-onset patients with GHD have increased total and visceral fat, low bone
mass, reduced muscle strength and impaired anaerobic physical capacity, an unfavourable
cardiovascular profile, and low quality of life [106,107].
There is conflicting data regarding body composition and muscle structure and perfor-
mance after GH treatment. In a recent study, Andrade-Guimarães et al. (2019) [108] found
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that individuals with congenital untreated IGHD had better muscle strength parameters
adjusted for weight and fat-free mass than controls, and also exhibited greater peripheral
resistance to fatigue.
In adults with GHD, Díez et al. (2018) [109] and Jørgensen et al. (2018) [107] among
others, argued in favour of the beneficial effects of GH administration on body composition,
muscle exercise capacity, bone structure and serum lipids. By contrast, He and Barkan
(2020) [110] critically reviewed the evidence of treatment benefits in adult-onset GHD.
They found most of the data inconsistent, thus recommending that GH treatment should
be a personalised decision.
Regarding GH resistance (LS) syndrome, the main clinical characteristics are dwarfism,
specific facial features such as a protruding forehead in the presence of a subnormal
head circumference, sparse hair, skeletal and muscular underdevelopment, obesity and
underdeveloped genitalia [111]. Long-term observations have shown that these individuals
are protected from cancer [112,113]. In relation to the muscle, they have a reduced lean
body mass and reduced muscle force and endurance [114]. Curiously, growth velocity
obtained with IGF-I administration is smaller than that observed with hGH in children
with congenital isolated GH deficiency [115]. Muscle benefit with IGF-1 therapy has not
been fully established. Long-term treatment for adult patients living with LS aimed at
strengthening the muscular and skeletal systems is not currently approved.
8. Muscle Impairment in Human Acromegaly
Muscular weakness and pain represent one of the significant disabling co-morbidities
in ACRO [5,116] and, as above mentioned, despite long-term remission of the disease,
this co-morbidity may persist and deeply compromise QoL. Although musculoskeletal
pain is reported in up to 90%, it is not usually recorded in the clinical history [116]. It should
be noted that as a result of treatment improvement, life expectancy in people living with
ACRO is currently comparable to that of the general population [117] and, therefore,
the rate of musculoskeletal impairment is not expected to be reduced. Nevertheless, this is
one of the least studied co-morbidities [118], and there are few studies focused on the
evolution of myopathy after ACRO treatment.
Mastaglia et al. in 1970 [119] reported for the first time on muscle impairment in ACRO.
Mild proximal muscle weakness was present in six out of 11 cases. Histological changes
in hypertrophy of both type-I and type-II muscle fibres were current in five out of nine
biopsy specimens taken from a proximal limb muscle. However, electron microscopy
showed a patchy myopathy process, thus accounting for these patients’ weakness and
myalgia. By contrast, Nagulesparen et al. (1976) [120] studied 18 patients with acromegaly
of varying degrees of severity; half of the specimens showed hypertrophy of type 1 fibres,
and atrophy in type 2 fibres, although a direct correlation between muscle appearances
and growth hormone levels was not observed.
These findings suggest, firstly, a dissociation between muscle macro/microstructure
and the IGF-1/GH level, and secondly an alteration in the damage repair mechanism in
acromegaly. Thus, other factors independently of hormone levels could play a key role
in ACRO myopathy, and treatments strengthening the muscle damage repair mechanism
could improve this co-morbidity.
Concerning energy consumption, Szendroedi et al. (2008) [121], found that patients
with ACRO exhibited reduced muscular ATP synthesis and oxidative capacity that may
persist despite the normalisation of GH secretion. Regarding strength, Füchtbauer et al.
(2017) [5] studied ACRO patients at diagnosis (n = 48), one year after surgery (n = 29)
and after long-term follow-up (median 11 years) (n = 24), compared to healthy subjects.
They found reduced grip and strength in active ACRO and increased proximal muscle
fatigue even after GH/IGF-1 normalisation.
Although the most apparent muscular structural change in active ACRO seemed
to be hypertrophy [122,123], more recent studies, have not confirmed this finding [124].
Recently Gokce et al. (2020) [125] using ultrasound found that the thicknesses of many
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components of the quadriceps muscle were lower in ACRO patients than control subjects
matched by age, sex and the body mass index.
We have very little evidence on interventional programs to improve this devastating
co-morbidity. However, Lima et al. (2019) [6] evaluated the effects of a functional home
rehabilitation program in seventeen adults with ACRO that resulted in improvements in
muscle function, functional capacity, general fatigue, body balance, and QoL.
Accordingly, other therapeutic strategies apart from GH/IGF-1 normalisation, with
a direct impact on muscle structure/performance should be followed to improve our
patients QoL.
9. Concluding Remarks and Future Perspectives
In ACRO, the sustained increase of GH and IGF-1 critically affects the skeletal, muscu-
lar system with severe repercussions on life quality. At present, our knowledge regarding
the underlying mechanisms and outcome of different treatments is scarce.
In addition, there are no clinical guidelines or any structured recommendations for
dealing with this debilitating co-morbidity. Therefore, there is a pressing need to promote
interaction between basic and clinical research, improving our knowledge and permitting
us to design therapeutic strategies.
Nevertheless, we can remark on some important points: (1) Up to 90% of ACRO
patients suffer from musculoskeletal pain. (2) This co-morbidity may persist despite
biochemical control of the disease and deeply compromise QoL. (3) Other factors apart
from GH/IGF-1 levels could have a significant role in ACRO myopathy’s underlying
mechanism. (4) New biomarkers linking muscle mass and metabolism to diagnose better
and phenotype myopathy and design the best therapeutic strategy are needed.
Cell lines and transgenic mice give important insights into the many actions of GH and
IGF-1. The degree of the contribution of GH or IGF-1 to myopathy in acromegaly remains
to be further investigated. In the clinical setting, we need (1) tools that efficiently and
reliably permit us to evaluate the muscular status of patients with ACRO, (2) collaborative,
multicentre studies with larger samples to provide more accurate data, and (3) further
studies that investigate treatments that directly influence muscle performance, even in
patients in remission.
Finally, it should be emphasised that the muscle should be seen as a key role organ,
with mechanical and metabolic functions. Disturbances in metabolic processes (for ex-
ample, hyperglycaemia, amino acid deficiency) can ultimately impact muscle structure
and, vice versa, changes in fibre type can promote metabolic changes. In this regard,
studies aimed at assessing the molecular link between structural changes and metabolic
function are needed.
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